China’s Permanent Mission to the United Nations held a briefing at UN Headquarters on July 31 regarding the 2026 World Artificial Intelligence Conference and the High-Level Meeting on Global AI Governance.
Fu Cong, China’s Permanent Representative to the UN, stated that President Xi Jinping put forward a comprehensive set of Chinese proposals at the opening ceremony of the conference. These proposals covered building a global AI governance system, upholding a people-centered and morally-sound approach, helping the Global South bridge the intelligence gap, establishing a World Artificial Intelligence Cooperation Organization (WAICO), and supporting the UN’s role in global AI governance, all of which made significant contributions to global AI governance. China will uphold the principles of open source, openness, win-win cooperation, and extensive consultation, joint contribution and shared benefits. On the broad platform of the UN, China stands ready to work with all parties to deliberate on major issues concerning the future of global AI governance.
United Nations Special Envoy for Digital and Emerging Technologies Amandeep Singh Gill said the World AI Conference is of landmark significance and expressed hope that WAICO would engage in close collaboration with the UN. Song Haitao, a member of the UN’s Independent International Scientific Panel on AI, also shared his experience attending the conference.
On July 16, 29 countries from Asia, Africa, Latin America and Europe signed the Agreement on the Establishment of the World Artificial Intelligence Cooperation Organization, becoming founding members. This marks an important milestone in advancing China’s initiative to establish WAICO.
According to the organizers, representatives from over 70 countries and international organizations attended the briefing. Participants congratulated China on the successful convening of the World AI Conference, spoke highly of President Xi’s important views, propositions and cooperation initiatives on AI governance, welcomed the establishment of WAICO, and expressed their readiness to jointly implement the cooperation initiatives announced at the conference. They voiced support for strengthening capacity-building in developing countries to achieve inclusive, shared and mutually beneficial outcomes.
Source: XINHUA
2026-08-03
details
Amazed by the conservation efforts at the Minjiang River Estuary Wetland in #Fuzhou, Ali Awwad, the Technology Editor at Al-Akhbar (Lebanon), said: "I like how they are protecting the environment."
Source: Fudao Funway
2026-07-31
details
SHENZHEN, July 28 (Xinhua) -- Chinese Vice Premier He Lifeng attended and addressed the opening ceremony of the 2026 APEC Ministerial Meeting on Forestry on Tuesday in Shenzhen, south China's Guangdong Province.
He noted that China has undergone historic, transformative and comprehensive changes in ecological conservation, both in understanding and in practices.
While achieving rapid economic growth and long-term social stability, China has found a path to modernization that features harmony between humanity and nature, he said.
He emphasized that the Asia-Pacific region is one of the areas with the richest forest resources and the most diverse ecosystems in the world, accounting for more than half of the global forest area.
China has been committed to safeguarding global ecological security and promoting ecological culture and green concepts, contributing Chinese wisdom and solutions to ecological conservation in the Asia-Pacific region and beyond, he said, adding that with joint efforts of all parties, the region has become a major force in reversing the downward trend of global forest resources.
In the face of the current ecological situation in the Asia-Pacific region, China will accelerate its green transformation of economic and social development, he said, adding that the country stands ready to work with all parties to jointly promote high-quality forestry development in the region.
Source: XINHUA
2026-07-29
details
Sourcec: Chinadaily.com.cn
2026-07-27
details
On May 28, the Ministry of Natural Resources, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Health Commission, the State Administration for Market Regulation, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration jointly issued the Guiding Opinions on Accelerating the High-Quality Development of Marine Medicines and Functional Products (hereinafter referred to as the Guiding Opinions). The Guiding Opinions systematically plan for the deep integration of scientific and technological innovation with industrial innovation in the marine biomedical sector, and coordinate efforts to strengthen the full-chain innovation system encompassing the "resource chain, technology chain, industrial chain, and application chain," thereby charting the course for making China's marine biomedical industry stronger, better, and larger.
I. The Medicinal Uniqueness of Marine Organisms and Their Immense Development Potential
Oceans cover 71% of the Earth's surface. In particular, the number of undiscovered microbial species in the deep sea and polar regions is estimated to be more than ten times that on land, rendering the ocean an "unknown treasure trove" of new medicines and novel functional genes. First, their unique structures offer significant advantages for source innovation. Having evolved over extended periods in extreme environments, such as high pressure, high salinity, low temperatures, and darkness, marine organisms produce secondary metabolites with novel structures and diverse skeletons, serving as a source of new medicines that cannot be replaced by terrestrial natural products. Second, they exhibit strong bioactivity and high potential for development into medicines. The conversion rate of lead compounds is far higher than that of terrestrial resources, making them more amenable to development into Class 1 innovative medicines or improved new medicines. Third, their distinctive efficacy aligns well with clinical needs. Marine active substances (such as polysaccharides, peptides, and saponins) possess unique therapeutic advantages in inhibiting tumor invasion and metastasis, regulating immune balance, promoting neural repair, accelerating wound healing, and providing antioxidant and anti-aging effects. Fourth, they have a pronounced "medicine-food homology" attribute andbroad application scenarios. Most marine medicinal materials (such as seaweed and sea cucumber) serve both as traditional Chinese medicinal ingredients and food raw materials, making them naturally suitable for the full-chain development of foods for special medical purposes, health foods, traditional Chinese medicine preparations, and innovative medicines, offering substantial cross-sector potential. However, deep-sea and polar biological resources are scarce and difficult to collect, conferring a monopolistic character; their low content of active substances, difficulties in separation and purification, and challenges in large-scale preparation create both technological and resource barriers. Accelerating the exploration and development potential assessment of marine medicinal biological resources plays a fundamental role in supporting the high-quality development of the marine biomedical industry.
The Guiding Opinions propose key measures such as improving the marine medicinal resource preservation system, strengthening the supply security of raw materials for marine biomanufacturing, and enhancing mechanisms for sharing basic resource services. These measures will effectively promote the conservation and efficient utilization of marine medicinal resources, consolidate the material foundation for independent innovation in China's marine biomedical industry, and provide critical support for breaking through resource bottlenecks and ensuring sustainable industrial development.
II. Marine Biomedical Development as a Highly Interdisciplinary and Technology-Intensive Field
Marine biomedical research spans multiple disciplines, including marine biology, natural product chemistry, traditional Chinese medicine, molecular pharmacology, bioengineering, and clinical medicine, making it a cutting-edge interdisciplinary emerging field. Since the successful development of China's first modern marine medicine, propylene glycol alginate sodium sulfate (PSS), in 1985, China's pace of "seeking medicines from the sea" has been accelerating. To date, China has cumulatively discovered approximately 14,000 marine natural products with novel structures, accounting for about 35% of the global total, with basic research remaining highly active. China has also built the world's largest marine microbial resource repository. However, overall, China's marine biomedical sector still faces challenges such as "more basic research, less clinical translation," insufficient industry-academia-research-application collaboration, a lack of national-level innovation platforms, and poor pilot-scale translation services. Accelerating technological breakthroughs is the key to high-quality industrial development.
The Guiding Opinions propose strengthening support for scientific and technological innovation. First, build high-caliber innovation platforms. Accelerate the development of national-level innovation platforms, and deploy translational medicine platforms for the "Blue Medicine Treasury," along with public service platforms for translation of research outcomes such as proof-of-concept centers and pilot-scale amplification platforms. Second, intensify research on key technologies, and improve the technological and process systems for discovering active substances and their large-scale preparation. Innovate "AI + marine medicine" technologies, build high-quality datasets, develop large AI models for intelligent marine drug discovery. Third, improve the technological system for the development of deep-sea biological genetic resources. These measures will effectively break through the technological bottlenecks and translational barriers in China's marine biomedical sector, accelerating the conversion of scientific and technological achievements into tangible productive forces.
III. Accelerating the Development of the Marine Biomedical Industry Holds Dual Strategic Significance
Accelerating efforts to make China's marine biomedical industry stronger, better, and larger will, on the one hand, effectively safeguard national pharmaceutical and health security and address the "bottleneck" issue in the source of new medicines. Building an independently patented "Blue Medicine Treasury" will help consolidate the nation's strategic biopharmaceutical security baseline and address shortcomings in the prevention and treatment of major diseases. On the other hand, it will foster new quality productive forces in the marine sector. Marine biomedicine is a high-value-added, technology-intensive strategic emerging industry. By 2025, the added value of China's marine medicine and biological products industry had reached 99.6 billion yuan. Developing this industry aligns with the requirements of the 15th Five-Year Plan and the coastal provinces' and cities' goals of "seeking strength from the sea."
The Guiding Opinions set forth breakthrough directions for key sectors, such as marine medicines, marine health foods, marine biomaterials, and marine biomanufactured products, which will accelerate the development of a modern marine biomedical industrial system and effectively enhance the industry's core competitiveness.
With regard to optimizing the industrial geographical layout, the Guiding Opinions encourage all localities to leverage their specific resource and technological advantages to develop industrial clusters with differentiated positioning. Support is provided for Qingdao, Shanghai, Ningbo, and Xiamen to develop distinctive clusters; coastal areas in southern China are encouraged to accelerate the development of tropical marine biological resources. This will foster a development pattern featuring complementary advantages and coordinated linkages.
IV. Strengthening Application Scenario Guidance to Expand the Space for Industrial Development
Marine biomedicine is characterized by high technological risks and long cycles, and faces challenges such as low consumer awareness. There is an urgent need to strengthen application scenario guidance to accelerate the transition of research outcomes from laboratories to practical applications.
The Guiding Opinions propose promoting the application of marine medicines, medical devices, health foods, and new food raw materials; optimizing industry alliance mechanisms; cultivating new consumption trends; and supporting high-quality products in building "China-chic brands." Additionally, they call for strengthening cross-departmental coordination and diversified funding investment to safeguard market promotion. These measures will provide targeted impetus for expanding the space for industrial development.
Source: Third Institute of Oceanography, Ministry of Natural Resources
2026-07-24
details
OFFICIAL WECHAT
Email：
secretariat_21cmcc@163.com
Telephone：
+86-591-83532970
+86-591-83533101
Fax：
+86-591-83531520
Address：
Room 728, Building 3, Eastern Municipal Government Office Compound, 193 South Riverside West Avenue, Cangshan District, Fuzhou City, Fujian Province, China
Set As Default Home Page|Add To Favorites|CONTACT US
Copyright: © 21st-Century Maritime Cooperation Committee Public security record number：35010402351060 闽ICP备2020019451号